Clinical guidelines include the use of granulocyte colony-stimulating factor to reduce risk of treatment delays resulting from neutropenia; however, because of cost, these agents were not available to our patients.9 Although still costly despite recently becoming available in generic formulary, granulocyte colony-stimulating factor could be considered for neutropenic patients in subsequent cycles. This evidence concerns the gene CSF3 and Decreased total neutrophil count.